Cellectar Biosciences (CLRB) Convertible Debt (2010 - 2014)

Cellectar Biosciences (CLRB) posted Convertible Debt of $3.8 million for Q2 2014, up 0.84% sequentially from $3.8 million in Q1 2014.

Cellectar Biosciences (CLRB) Convertible Debt (2010 - 2014) Analysis & Trends

Cellectar Biosciences has reported Convertible Debt for 2 years, with the latest figure at $3.8 million in Q2 2014.

Quarterly Convertible Debt changed N/A year-over-year to $3.8 million in Q2 2014, while the trailing twelve-month figure through Jun 2014 was $3.8 million (changed N/A YoY) and the FY2010 annual result came in at $2.7 million, changed N/A from the prior year.
Convertible Debt rose to $3.8 million in Q2 2014 per CLRB's latest filing, from $3.8 million in the prior quarter.
Over five years, Convertible Debt peaked at $3.8 million in Q2 2014 and troughed at $2.7 million in Q4 2010.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Cellectar Biosciences	6.63 Mn	6.63 Mn	-

Download Data